6	CD	6	6	6	N	O
ADVERSE	JJ	adverse	adverse	advers	N	O
REACTIONS	NN	reactions	reaction	reaction	N	O

The	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
serious	JJ	serious	serious	seriou	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
are	VBP	are	are	are	N	O
discussed	VBN	discussed	discussed	discuss	N	O
in	IN	in	in	in	N	O
greater	JJR	greater	greater	greater	N	O
detail	NN	detail	detail	detail	N	O
in	IN	in	in	in	N	O
another	DT	another	another	anoth	N	O
section	NN	section	section	section	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
label	NN	label	label	label	N	O
:	:	:	:	:	N	O

Bone	NNP	bone	bone	bone	N	B-AdverseReaction
Marrow	NNP	marrow	marrow	marrow	N	I-AdverseReaction
Suppression	NNP	suppression	suppression	suppress	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
Adverse	NNP	adverse	adverse	advers	N	I-AdverseReaction
Reactions	NNP	reactions	reaction	reaction	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
Failure	NN	failure	failure	failur	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Elderly	NNP	elderly	elderly	elderli	Y	O
Patients	NNPS	patients	patient	patient	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Hepatic	NNP	hepatic	hepatic	hepat	N	O
Impairment	NNP	impairment	impairment	impair	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.6	CD	5.6	5.6	5.6	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Embryo	NNP	embryo	embryo	embryo	N	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
Fetal	JJ	fetal	fetal	fetal	N	I-AdverseReaction
Toxicity	NNP	toxicity	toxicity	toxic	N	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

EXCERPT	NNS	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Most	JJS	most	most	most	N	O
common	JJ	common	common	common	N	O
all	DT	all	all	all	N	O
grades	NNS	grades	grade	grade	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
are	VBP	are	are	are	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
anorexia	NN	anorexia	anorexia	anorexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysgeusia	NN	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
.	.	.	.	.	N	O

(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O

To	TO	to	to	to	N	O

report	NN	report	report	report	N	O
SUSPECTED	NNP	suspected	suspected	suspect	N	O
ADVERSE	NNP	adverse	adverse	advers	N	O
REACTIONS	NNP	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
contact	NN	contact	contact	contact	N	O
sanofi	SYM	sanofi	sanofi	sanofi	N	O
-	:	-	-	-	N	O
aventis	NN	aventis	aventis	aventi	N	O
U.S.	NNP	u.s.	u.s.	u.s.	N	O

LLC	NNP	llc	llc	llc	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
633	CD	633	633	633	N	O
-	:	-	-	-	N	O
1610	CD	1610	1610	1610	N	O
or	CC	or	or	or	N	O
FDA	NNP	fda	fda	fda	N	O
at	IN	at	at	at	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
800	CD	800	800	800	N	O
-	:	-	-	-	N	O
FDA	NNP	fda	fda	fda	N	O
-	:	-	-	-	N	O
1088	CD	1088	1088	1088	N	O
or	CC	or	or	or	N	O
www	VB	www	www	www	N	O
.	.	.	.	.	N	O
fda	NN	fda	fda	fda	N	O
.	.	.	.	.	N	O
gov	JJ	gov	gov	gov	N	O
medwatch	NN	medwatch	medwatch	medwatch	N	O
.	.	.	.	.	N	O

6.1	CD	6.1	6.1	6.1	N	O

Clinical	JJ	clinical	clinical	clinic	N	O
Trial	NNP	trial	trial	trial	N	O
Experience	NN	experience	experience	experi	N	O

Because	IN	because	because	becaus	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
are	VBP	are	are	are	N	O
conducted	VBN	conducted	conducted	conduct	N	O
under	IN	under	under	under	N	O
widely	RB	widely	widely	wide	N	O
varying	VBG	varying	varying	vari	N	O
conditions	NNS	conditions	condition	condit	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
cannot	JJ	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
directly	RB	directly	directly	directli	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
rates	NNS	rates	rate	rate	N	O
in	IN	in	in	in	N	O
other	JJ	other	other	other	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	O
not	RB	not	not	not	N	O
reflect	VB	reflect	reflect	reflect	N	O
the	DT	the	the	the	N	O
rates	NNS	rates	rate	rate	N	O
observed	VBD	observed	observed	observ	N	O
in	IN	in	in	in	N	O
clinical	JJ	clinical	clinical	clinic	N	O
practice	NN	practice	practice	practic	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
safety	NN	safety	safety	safeti	N	O
of	IN	of	of	of	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
in	IN	in	in	in	N	O
combination	NN	combination	combination	combin	N	O
with	IN	with	with	with	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
was	VBD	was	wa	wa	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
in	IN	in	in	in	N	O
371	CD	371	371	371	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hormone	JJ	hormone	hormone	hormon	N	O
-	:	-	-	-	N	O
refractory	NN	refractory	refractory	refractori	N	O
metastatic	JJ	metastatic	metastatic	metastat	N	O
prostate	NN	prostate	prostate	prostat	N	O
cancer	NN	cancer	cancer	cancer	Y	O
treated	VBN	treated	treated	treat	N	O
in	IN	in	in	in	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
randomized	JJ	randomized	randomized	random	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
mitoxantrone	VB	mitoxantrone	mitoxantrone	mitoxantron	N	O
plus	CC	plus	plus	plu	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
.	.	.	.	.	N	O

Deaths	NNS	deaths	death	death	N	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
causes	VBZ	causes	cause	caus	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
disease	JJ	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
within	IN	within	within	within	N	O
30	CD	30	30	30	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
last	JJ	last	last	last	N	O
study	JJ	study	study	studi	N	O
drug	NN	drug	drug	drug	N	O
dose	NN	dose	dose	dose	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
mitoxantrone	NN	mitoxantrone	mitoxantrone	mitoxantron	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
were	VBD	were	were	were	N	O
infections	NNS	infections	infection	infect	N	B-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
5	CD	5	5	5	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
(	(	(	(	(	N	O
n	JJ	n	n	n	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
majority	NN	majority	majority	major	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
of	IN	of	of	of	N	O
5	CD	5	5	5	N	O
patients	NNS	patients	patient	patient	N	O
)	)	)	)	)	N	O
of	IN	of	of	of	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
infection	NN	infection	infection	infect	Y	B-AdverseReaction
-	:	-	-	-	N	I-AdverseReaction
related	JJ	related	related	relat	N	I-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
after	IN	after	after	after	N	O
a	DT	a	a	a	N	O
single	JJ	single	single	singl	N	O
dose	NN	dose	dose	dose	N	O
of	IN	of	of	of	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
included	VBD	included	included	includ	N	O
ventricular	JJ	ventricular	ventricular	ventricular	N	B-AdverseReaction
fibrillation	NN	fibrillation	fibrillation	fibril	Y	I-AdverseReaction
,	,	,	,	,	N	O
cerebral	JJ	cerebral	cerebral	cerebr	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
grade	VBD	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
anemia	RB	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
,	,	,	,	,	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
abdominal	JJ	abdominal	abdominal	abdomin	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
back	RB	back	back	back	N	B-AdverseReaction
pain	NN	pain	pain	pain	Y	I-AdverseReaction
,	,	,	,	,	N	O
anorexia	NN	anorexia	anorexia	anorexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
peripheral	JJ	peripheral	peripheral	peripher	N	B-AdverseReaction
neuropathy	NN	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
,	,	,	,	,	N	O
dyspnea	NN	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
,	,	,	,	,	N	O
dysguesia	NN	dysguesia	dysguesia	dysguesia	N	B-AdverseReaction
,	,	,	,	,	N	O
cough	NN	cough	cough	cough	Y	B-AdverseReaction
,	,	,	,	,	N	O
arthralgia	NN	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
alopecia	NN	alopecia	alopecia	alopecia	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
grade	VBD	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
were	VBD	were	were	were	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
leukopenia	NN	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
asthenia	NN	asthenia	asthenia	asthenia	Y	B-AdverseReaction
.	.	.	.	.	N	O

Treatment	JJ	treatment	treatment	treatment	N	O
discontinuations	NNS	discontinuations	discontinuation	discontinu	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
adverse	JJ	adverse	adverse	advers	N	O
drug	NN	drug	drug	drug	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
18%	CD	18%	18%	18%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
and	CC	and	and	and	N	O
8%	CD	8%	8%	8%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
received	VBD	received	received	receiv	N	O
mitoxantrone	NN	mitoxantrone	mitoxantrone	mitoxantron	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
group	NN	group	group	group	N	O
were	VBD	were	were	were	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
.	.	.	.	.	N	O

Dose	JJ	dose	dose	dose	N	O
reductions	NNS	reductions	reduction	reduct	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
12%	CD	12%	12%	12%	N	O
of	IN	of	of	of	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
mitoxantrone	NN	mitoxantrone	mitoxantrone	mitoxantron	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
delays	NNS	delays	delay	delay	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
28%	CD	28%	28%	28%	N	O
of	IN	of	of	of	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
15%	CD	15%	15%	15%	N	O
of	IN	of	of	of	N	O
mitoxantrone	NN	mitoxantrone	mitoxantrone	mitoxantron	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Table	JJ	table	table	tabl	N	O
2	CD	2	2	2	N	O
-	:	-	-	-	N	O
Incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
Reported	NNP	reported	reported	report	N	O
Adverse	NNP	adverse	adverse	advers	N	O
ReactionsGraded	VBD	reactionsgraded	reactionsgraded	reactionsgrad	N	O
using	VBG	using	using	use	N	O
NCI	NNP	nci	nci	nci	N	O
CTCAE	NNP	ctcae	ctcae	ctcae	N	O
version	NN	version	version	version	N	O
3	CD	3	3	3	N	O
and	CC	and	and	and	N	O
Hematologic	NNP	hematologic	hematologic	hematolog	N	B-AdverseReaction
Abnormalities	NNP	abnormalities	abnormality	abnorm	N	I-AdverseReaction
in	IN	in	in	in	N	O
5%	CD	5%	5%	5%	N	O
of	IN	of	of	of	N	O
Patients	NNS	patients	patient	patient	N	O
Receiving	VBG	receiving	receiving	receiv	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
in	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Prednisone	NNP	prednisone	prednisone	prednison	N	O
or	CC	or	or	or	N	O
Mitoxantrone	NNP	mitoxantrone	mitoxantrone	mitoxantron	N	O
in	IN	in	in	in	N	O
Combination	NNP	combination	combination	combin	N	O
with	IN	with	with	with	N	O
Prednisone	NNP	prednisone	prednisone	prednison	N	O

JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
25	CD	25	25	25	N	O
mg	NN	mg	mg	mg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
with	IN	with	with	with	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
dailyn	NN	dailyn	dailyn	dailyn	N	O
371	CD	371	371	371	N	O
Mitoxantrone	NNP	mitoxantrone	mitoxantrone	mitoxantron	N	O
12	CD	12	12	12	N	O
mg	NN	mg	mg	mg	N	O
m	NN	m	m	m	N	O
2	CD	2	2	2	N	O
every	DT	every	every	everi	N	O
3	CD	3	3	3	N	O
weeks	NNS	weeks	week	week	N	O
with	IN	with	with	with	N	O
prednisone	NN	prednisone	prednisone	prednison	N	O
10	CD	10	10	10	N	O
mg	NN	mg	mg	mg	N	O
dailyn	NN	dailyn	dailyn	dailyn	N	O
371	CD	371	371	371	N	O

Grade	$	grade	grade	grade	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
n	NNS	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
n	NNS	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
1	CD	1	1	1	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
n	NNS	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O
Grade	VBD	grade	grade	grade	N	O
3	CD	3	3	3	N	O
-	:	-	-	-	N	O
4	CD	4	4	4	N	O
n	NNS	n	n	n	N	O
(	(	(	(	(	N	O
)	)	)	)	)	N	O

Any	DT	any	any	ani	N	O

Adverse	JJ	adverse	adverse	advers	N	O
Reaction	NN	reaction	reaction	reaction	N	O

Blood	NN	blood	blood	blood	N	O
and	CC	and	and	and	N	O
Lymphatic	NNP	lymphatic	lymphatic	lymphat	N	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
347	CD	347	347	347	N	O
(	(	(	(	(	N	O
94%	CD	94%	94%	94%	N	O
)	)	)	)	)	N	O
303	CD	303	303	303	N	O
(	(	(	(	(	N	O
82%	CD	82%	82%	82%	N	O
)	)	)	)	)	N	O
325	CD	325	325	325	N	O
(	(	(	(	(	N	O
87%	CD	87%	87%	87%	N	O
)	)	)	)	)	N	O
215	CD	215	215	215	N	O
(	(	(	(	(	N	O
58%	CD	58%	58%	58%	N	O
)	)	)	)	)	N	O

Febrile	NNP	febrile	febrile	febril	N	B-AdverseReaction
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Anemia	$	anemia	anemia	anemia	Y	B-AdverseReaction
361	CD	361	361	361	N	O
(	(	(	(	(	N	O
98%	CD	98%	98%	98%	N	O
)	)	)	)	)	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
302	CD	302	302	302	N	O
(	(	(	(	(	N	O
82%	CD	82%	82%	82%	N	O
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O

Leukopenia	NNP	leukopenia	leukopenia	leukopenia	Y	B-AdverseReaction
355	CD	355	355	355	N	O
(	(	(	(	(	N	O
96%	CD	96%	96%	96%	N	O
)	)	)	)	)	N	O
253	CD	253	253	253	N	O
(	(	(	(	(	N	O
69%	CD	69%	69%	69%	N	O
)	)	)	)	)	N	O
343	CD	343	343	343	N	O
(	(	(	(	(	N	O
93%	CD	93%	93%	93%	N	O
)	)	)	)	)	N	O
157	CD	157	157	157	N	O
(	(	(	(	(	N	O
42%	CD	42%	42%	42%	N	O
)	)	)	)	)	N	O

Thrombocytopenia	NNP	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
176	CD	176	176	176	N	O
(	(	(	(	(	N	O
48%	CD	48%	48%	48%	N	O
)	)	)	)	)	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
160	CD	160	160	160	N	O
(	(	(	(	(	N	O
43%	CD	43%	43%	43%	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Cardiac	JJ	cardiac	cardiac	cardiac	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Arrhythmia	$	arrhythmia	arrhythmia	arrhythmia	Y	B-AdverseReaction
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Diarrhea	NNP	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
173	CD	173	173	173	N	O
(	(	(	(	(	N	O
47%	CD	47%	47%	47%	N	O
)	)	)	)	)	N	O
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
127	CD	127	127	127	N	O
(	(	(	(	(	N	O
34%	CD	34%	34%	34%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
85	CD	85	85	85	N	O
(	(	(	(	(	N	O
23%	CD	23%	23%	23%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
83	CD	83	83	83	N	O
(	(	(	(	(	N	O
22%	CD	22%	22%	22%	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
38	CD	38	38	38	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Constipation	NN	constipation	constipation	constip	Y	B-AdverseReaction
76	CD	76	76	76	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
57	CD	57	57	57	N	O
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
64	CD	64	64	64	N	O
(	(	(	(	(	N	O
17%	CD	17%	17%	17%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Dyspepsia	NNP	dyspepsia	dyspepsia	dyspepsia	Y	B-AdverseReaction
36	CD	36	36	36	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

General	NNP	general	general	gener	N	O
Disorders	NNP	disorders	disorder	disord	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
Site	NNP	site	site	site	N	O
Conditions	NNS	conditions	condition	condit	N	O

Fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
136	CD	136	136	136	N	O
(	(	(	(	(	N	O
37%	CD	37%	37%	37%	N	O
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
102	CD	102	102	102	N	O
(	(	(	(	(	N	O
27%	CD	27%	27%	27%	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Asthenia	NNP	asthenia	asthenia	asthenia	Y	B-AdverseReaction
76	CD	76	76	76	N	O
(	(	(	(	(	N	O
20%	CD	20%	20%	20%	N	O
)	)	)	)	)	N	O
17	CD	17	17	17	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
46	CD	46	46	46	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Pyrexia	$	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
45	CD	45	45	45	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
23	CD	23	23	23	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
Edema	NNP	edema	edema	edema	Y	I-AdverseReaction
34	CD	34	34	34	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
34	CD	34	34	34	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Mucosal	NNP	mucosal	mucosal	mucos	N	B-AdverseReaction
Inflammation	NNP	inflammation	inflammation	inflamm	Y	I-AdverseReaction
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Pain	NN	pain	pain	pain	Y	B-AdverseReaction
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O

Infections	NNS	infections	infection	infect	N	O
and	CC	and	and	and	N	O
Infestations	NNS	infestations	infestation	infest	N	O

Urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
Tract	NNP	tract	tract	tract	N	I-AdverseReaction
Infection	NNP	infection	infection	infect	Y	I-AdverseReaction
29	CD	29	29	29	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
6	CD	6	6	6	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Investigations	NNS	investigations	investigation	investig	N	O

Weight	NNP	weight	weight	weight	Y	B-AdverseReaction
Decreased	VBD	decreased	decreased	decreas	N	I-AdverseReaction
32	CD	32	32	32	N	O
(	(	(	(	(	N	O
9%	CD	9%	9%	9%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
28	CD	28	28	28	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Metabolism	NN	metabolism	metabolism	metabol	N	O
and	CC	and	and	and	N	O
Nutrition	NN	nutrition	nutrition	nutrit	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Anorexia	$	anorexia	anorexia	anorexia	Y	B-AdverseReaction
59	CD	59	59	59	N	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
8	CD	8	8	8	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Musculoskeletal	NNP	musculoskeletal	musculoskeletal	musculoskelet	N	O
and	CC	and	and	and	N	O
Connective	NNP	connective	connective	connect	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Back	RB	back	back	back	N	B-AdverseReaction
Pain	NNP	pain	pain	pain	Y	I-AdverseReaction
60	CD	60	60	60	N	O
(	(	(	(	(	N	O
16%	CD	16%	16%	16%	N	O
)	)	)	)	)	N	O
14	CD	14	14	14	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
45	CD	45	45	45	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
11	CD	11	11	11	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O

Arthralgia	$	arthralgia	arthralgia	arthralgia	Y	B-AdverseReaction
39	CD	39	39	39	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
31	CD	31	31	31	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Muscle	NNP	muscle	muscle	muscl	N	B-AdverseReaction
Spasms	NNP	spasms	spasm	spasm	Y	I-AdverseReaction
27	CD	27	27	27	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
10	CD	10	10	10	N	O
(	(	(	(	(	N	O
3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Nervous	JJ	nervous	nervous	nervou	Y	O
System	NNP	system	system	system	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Peripheral	NNP	peripheral	peripheral	peripher	N	B-AdverseReaction
Neuropathy	NNP	neuropathy	neuropathy	neuropathi	Y	I-AdverseReaction
50	CD	50	50	50	N	O
(	(	(	(	(	N	O
13%	CD	13%	13%	13%	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
12	CD	12	12	12	N	O
(	(	(	(	(	N	O
3.2%	CD	3.2%	3.2%	3.2%	N	O
)	)	)	)	)	N	O
3	CD	3	3	3	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Dysgeusia	NNP	dysgeusia	dysgeusia	dysgeusia	Y	B-AdverseReaction
41	CD	41	41	41	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
15	CD	15	15	15	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
30	CD	30	30	30	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
21	CD	21	21	21	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Headache	$	headache	headache	headach	Y	B-AdverseReaction
28	CD	28	28	28	N	O
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
19	CD	19	19	19	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Renal	NNP	renal	renal	renal	N	O
and	CC	and	and	and	N	O
Urinary	NNP	urinary	urinary	urinari	N	O
Tract	NNP	tract	tract	tract	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Hematuria	$	hematuria	hematuria	hematuria	Y	B-AdverseReaction
62	CD	62	62	62	N	O
(	(	(	(	(	N	O
17%	CD	17%	17%	17%	N	O
)	)	)	)	)	N	O
7	CD	7	7	7	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
13	CD	13	13	13	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Dysuria	NNP	dysuria	dysuria	dysuria	Y	B-AdverseReaction
25	CD	25	25	25	N	O
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
5	CD	5	5	5	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Respiratory	NNP	respiratory	respiratory	respiratori	N	O
,	,	,	,	,	N	O
Thoracic	NNP	thoracic	thoracic	thorac	N	O
and	CC	and	and	and	N	O
Mediastinal	NNP	mediastinal	mediastinal	mediastin	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Dyspnea	NNP	dyspnea	dyspnea	dyspnea	Y	B-AdverseReaction
43	CD	43	43	43	N	O
(	(	(	(	(	N	O
12%	CD	12%	12%	12%	N	O
)	)	)	)	)	N	O
4	CD	4	4	4	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O
16	CD	16	16	16	N	O
(	(	(	(	(	N	O
4%	CD	4%	4%	4%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Cough	IN	cough	cough	cough	Y	B-AdverseReaction
40	CD	40	40	40	N	O
(	(	(	(	(	N	O
11%	CD	11%	11%	11%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
22	CD	22	22	22	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Skin	NNP	skin	skin	skin	N	O
and	CC	and	and	and	N	O
Subcutaneous	NNP	subcutaneous	subcutaneous	subcutan	N	O
Tissue	NNP	tissue	tissue	tissu	N	O
Disorders	NNP	disorders	disorder	disord	N	O

Alopecia	$	alopecia	alopecia	alopecia	Y	B-AdverseReaction
37	CD	37	37	37	N	O
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O
18	CD	18	18	18	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
0	CD	0	0	0	N	O

Vascular	JJ	vascular	vascular	vascular	N	O
Disorders	NNS	disorders	disorder	disord	N	O

Hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
20	CD	20	20	20	N	O
(	(	(	(	(	N	O
5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
2	CD	2	2	2	N	O
(	(	(	(	(	N	O
1	CD	1	1	1	N	O
)	)	)	)	)	N	O
9	CD	9	9	9	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
1	CD	1	1	1	N	O
(	(	(	(	(	N	O
1%	CD	1%	1%	1%	N	O
)	)	)	)	)	N	O

Median	JJ	median	median	median	N	O

Duration	NN	duration	duration	durat	N	O
of	IN	of	of	of	N	O
Treatment	NNP	treatment	treatment	treatment	N	O
6	CD	6	6	6	N	O
cycles	NNS	cycles	cycle	cycl	N	O
4	CD	4	4	4	N	O
cycles	NNS	cycles	cycle	cycl	N	O

Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	O
and	CC	and	and	and	N	O
Associated	NNP	associated	associated	associ	N	O
Clinical	NNP	clinical	clinical	clinic	N	O
Events	NNS	events	event	event	N	O
:	:	:	:	:	N	O

Five	CD	five	five	five	N	O

patients	NNS	patients	patient	patient	N	O
experienced	VBD	experienced	experienced	experienc	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
infectious	JJ	infectious	infectious	infecti	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
or	CC	or	or	or	N	O
septic	JJ	septic	septic	septic	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
had	VBD	had	had	had	N	O
grade	VBN	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
had	VBD	had	had	had	N	O
febrile	VBN	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
additional	JJ	additional	additional	addit	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
death	NN	death	death	death	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
neutropenia	VB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
without	IN	without	without	without	N	B-Negation
a	DT	a	a	a	N	O
documented	JJ	documented	documented	document	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
.	.	.	.	.	N	O

Twenty	CD	twenty	twenty	twenti	N	O
-	:	-	-	-	N	O
two	CD	two	two	two	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
discontinued	VBN	discontinued	discontinued	discontinu	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
treatment	NN	treatment	treatment	treatment	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
neutropenia	VB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
,	,	,	,	,	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
most	RBS	most	most	most	N	O
common	JJ	common	common	common	N	O
adverse	JJ	adverse	adverse	advers	N	O
reaction	NN	reaction	reaction	reaction	N	O
leading	VBG	leading	leading	lead	N	O
to	TO	to	to	to	N	O
treatment	NN	treatment	treatment	treatment	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
group	NN	group	group	group	N	O
was	VBD	was	wa	wa	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
.	.	.	.	.	N	O

Hematuria	NNS	hematuria	hematuria	hematuria	Y	O
:	:	:	:	:	N	O

Adverse	JJ	adverse	adverse	advers	N	O
events	NNS	events	event	event	N	O
of	IN	of	of	of	N	O
hematuria	NNS	hematuria	hematuria	hematuria	Y	B-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
those	DT	those	those	those	N	O
requiring	VBG	requiring	requiring	requir	N	O
medical	JJ	medical	medical	medic	N	O
intervention	NN	intervention	intervention	intervent	N	O
,	,	,	,	,	N	O
were	VBD	were	were	were	N	O
more	JJR	more	more	more	N	O
common	JJ	common	common	common	N	O
in	IN	in	in	in	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
grade	NN	grade	grade	grade	N	B-Severity
2	CD	2	2	2	N	I-Severity
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
6%	CD	6%	6%	6%	N	O
in	IN	in	in	in	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
-	:	-	-	-	N	O
treated	VBD	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
and	CC	and	and	and	N	O
2%	CD	2%	2%	2%	N	O
in	IN	in	in	in	N	O
mitoxantrone	NN	mitoxantrone	mitoxantrone	mitoxantron	N	O
-	:	-	-	-	N	O
treated	JJ	treated	treated	treat	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

Other	JJ	other	other	other	N	O
factors	NNS	factors	factor	factor	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
hematuria	NNS	hematuria	hematuria	hematuria	Y	B-AdverseReaction
were	VBD	were	were	were	N	O
well	RB	well	well	well	N	O
-	:	-	-	-	N	O
balanced	VBN	balanced	balanced	balanc	N	O
between	IN	between	between	between	N	O
arms	NNS	arms	arm	arm	N	O
and	CC	and	and	and	N	O
do	VBP	do	do	do	N	O
not	RB	not	not	not	N	O
account	VB	account	account	account	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
increased	JJ	increased	increased	increas	N	O
rate	NN	rate	rate	rate	N	O
of	IN	of	of	of	N	O
hematuria	NN	hematuria	hematuria	hematuria	Y	B-AdverseReaction
on	IN	on	on	on	N	O
the	DT	the	the	the	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
arm	NN	arm	arm	arm	N	O
.	.	.	.	.	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	O
Laboratory	NNP	laboratory	laboratory	laboratori	N	O
Abnormalities	NNS	abnormalities	abnormality	abnorm	N	O
:	:	:	:	:	N	O

The	DT	the	the	the	N	O
incidences	NNS	incidences	incidence	incid	N	O
of	IN	of	of	of	N	O
grade	NN	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
increased	VBD	increased	increased	increas	N	B-AdverseReaction
AST	NNP	ast	ast	ast	N	I-AdverseReaction
,	,	,	,	,	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
ALT	NNP	alt	alt	alt	N	I-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
increased	VBD	increased	increased	increas	N	B-AdverseReaction
bilirubin	NNS	bilirubin	bilirubin	bilirubin	Y	I-AdverseReaction
were	VBD	were	were	were	N	O
each	DT	each	each	each	N	O
1%	CD	1%	1%	1%	N	O
.	.	.	.	.	N	O

Elderly	JJ	elderly	elderly	elderli	Y	O
Population	NN	population	population	popul	N	O
:	:	:	:	:	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
grade	NN	grade	grade	grade	N	B-Severity
1	CD	1	1	1	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
reported	VBN	reported	reported	report	N	O
at	IN	at	at	at	N	O
rates	NNS	rates	rate	rate	N	O
5%	CD	5%	5%	5%	N	O
higher	JJR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
or	CC	or	or	or	N	O
greater	JJR	greater	greater	greater	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
younger	JJR	younger	younger	younger	N	O
patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
fatigue	NN	fatigue	fatigue	fatigu	Y	B-AdverseReaction
(	(	(	(	(	N	O
40%	CD	40%	40%	40%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

30%	CD	30%	30%	30%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
97%	CD	97%	97%	97%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

89%	CD	89%	89%	89%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
asthenia	RB	asthenia	asthenia	asthenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
24%	CD	24%	24%	24%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

15%	CD	15%	15%	15%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
pyrexia	NN	pyrexia	pyrexia	pyrexia	Y	B-AdverseReaction
(	(	(	(	(	N	O
15%	CD	15%	15%	15%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

8%	CD	8%	8%	8%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
dizziness	NN	dizziness	dizziness	dizzi	Y	B-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

5%	CD	5%	5%	5%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
urinary	JJ	urinary	urinary	urinari	N	B-AdverseReaction
tract	NN	tract	tract	tract	N	I-AdverseReaction
infection	NN	infection	infection	infect	Y	I-AdverseReaction
(	(	(	(	(	N	O
10%	CD	10%	10%	10%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

3%	CD	3%	3%	3%	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
(	(	(	(	(	N	O
7%	CD	7%	7%	7%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
respectively	RB	respectively	respectively	respect	N	O
.	.	.	.	.	N	O

The	DT	the	the	the	N	O
incidence	NN	incidence	incidence	incid	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
following	VBG	following	following	follow	N	O
grade	NN	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
were	VBD	were	were	were	N	O
higher	JJR	higher	higher	higher	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
compared	VBN	compared	compared	compar	N	O
to	TO	to	to	to	N	O
younger	JJR	younger	younger	younger	N	O
patients	NNS	patients	patient	patient	N	O
;	:	;	;	;	N	O
neutropenia	CC	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
(	(	(	(	(	N	O
87%	CD	87%	87%	87%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

74%	CD	74%	74%	74%	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
(	(	(	(	(	N	O
8%	CD	8%	8%	8%	N	O
vs	NN	vs	v	vs	N	O
.	.	.	.	.	N	O

6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

6.2	CD	6.2	6.2	6.2	N	O
Postmarketing	VBG	postmarketing	postmarketing	postmarket	N	O
Experience	NN	experience	experience	experi	N	O

The	DT	the	the	the	N	O
following	JJ	following	following	follow	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
identified	VBN	identified	identified	identifi	N	O
from	IN	from	from	from	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trials	NNS	trials	trial	trial	N	O
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
post	VB	post	post	post	N	O
-	:	-	-	-	N	O
marketing	NN	marketing	marketing	market	N	O
surveillance	NN	surveillance	surveillance	surveil	N	O
.	.	.	.	.	N	O

Because	IN	because	because	becaus	N	O
they	PRP	they	they	they	N	O
are	VBP	are	are	are	N	O
reported	VBN	reported	reported	report	N	O
from	IN	from	from	from	N	O
a	DT	a	a	a	N	O
population	NN	population	population	popul	N	O
of	IN	of	of	of	N	O
unknown	JJ	unknown	unknown	unknown	N	O
size	NN	size	size	size	N	O
,	,	,	,	,	N	O
precise	JJ	precise	precise	precis	N	O
estimates	NNS	estimates	estimate	estim	N	O
of	IN	of	of	of	N	O
frequency	NN	frequency	frequency	frequenc	N	O
cannot	NN	cannot	cannot	cannot	N	O
be	VB	be	be	be	N	O
made	VBN	made	made	made	N	O
.	.	.	.	.	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
:	:	:	:	:	N	O
Gastritis	NN	gastritis	gastritis	gastriti	Y	B-AdverseReaction
,	,	,	,	,	N	O
intestinal	JJ	intestinal	intestinal	intestin	N	B-AdverseReaction
obstruction	NN	obstruction	obstruction	obstruct	Y	I-AdverseReaction
.	.	.	.	.	N	O
\n\n	VB	\n\n	\n\n	\n\n	N	O
BOXED	NNP	boxed	boxed	box	N	O
WARNING	NNP	warning	warning	warn	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
NEUTROPENIA	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
AND	NNP	and	and	and	N	O
HYPERSENSITIVITY	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
NEUTROPENIA	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
AND	NNP	and	and	and	N	O
HYPERSENSITIVITY	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
\n\n	NNP	\n\n	\n\n	\n\n	N	O
EXCERPT	NNP	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
WARNING	NN	warning	warning	warn	N	O
:	:	:	:	:	N	O
NEUTROPENIA	NNP	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
AND	NNP	and	and	and	N	O
HYPERSENSITIVITY	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
\n\n\n\n	NNP	\n\n\n\n	\n\n\n\n	\n\n\n\n	N	O
See	NNP	see	see	see	N	O
full	JJ	full	full	full	N	O
prescribing	VBG	prescribing	prescribing	prescrib	N	O
information	NN	information	information	inform	N	O
for	IN	for	for	for	N	O
complete	JJ	complete	complete	complet	N	O
boxed	JJ	boxed	boxed	box	N	O
warning	NN	warning	warning	warn	N	O
.	.	.	.	.	N	O

Neutropenic	JJ	neutropenic	neutropenic	neutropen	N	B-AdverseReaction
deaths	NNS	deaths	death	death	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Obtain	NNP	obtain	obtain	obtain	N	O
frequent	JJ	frequent	frequent	frequent	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
to	TO	to	to	to	N	O
monitor	VB	monitor	monitor	monitor	N	O
for	IN	for	for	for	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
.	.	.	.	.	N	O

Do	NNP	do	do	do	N	O
not	RB	not	not	not	N	O
give	VB	give	give	give	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
if	IN	if	if	if	N	O
neutrophil	JJ	neutrophil	neutrophil	neutrophil	N	O
counts	NNS	counts	count	count	N	O
are	VBP	are	are	are	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
500	CD	500	500	500	N	O
cells	NNS	cells	cell	cell	N	O
mm3	NN	mm3	mm3	mm3	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)(	RB	)(	)(	)(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
Severe	NNP	severe	severe	sever	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	B-Factor
include	VB	include	include	includ	N	O
generalized	JJ	generalized	generalized	gener	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
and	CC	and	and	and	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	B-AdverseReaction
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
immediately	RB	immediately	immediately	immedi	N	O
if	IN	if	if	if	N	O
severe	JJ	severe	severe	sever	N	O
reactions	NNS	reactions	reaction	reaction	N	O
occur	VBP	occur	occur	occur	N	O
and	CC	and	and	and	N	O
administer	VBP	administer	administer	administ	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)(	RB	)(	)(	)(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
\n	NN	\n	\n	\n	N	O
Contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
if	IN	if	if	if	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
to	TO	to	to	to	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
drugs	NNS	drugs	drug	drug	N	O
formulated	VBN	formulated	formulated	formul	N	O
with	IN	with	with	with	N	O
polysorbate	NN	polysorbate	polysorbate	polysorb	N	O
80	CD	80	80	80	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
\n	FW	\n	\n	\n	N	O
\n	FW	\n	\n	\n	N	O
\n\n	FW	\n\n	\n\n	\n\n	N	O
Neutropenia	NNP	neutropenia	neutropenia	neutropenia	Y	O
:	:	:	:	:	N	O
Neutropenic	JJ	neutropenic	neutropenic	neutropen	N	B-AdverseReaction
deaths	NNS	deaths	death	death	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
order	NN	order	order	order	N	O
to	TO	to	to	to	N	O
monitor	VB	monitor	monitor	monitor	N	O
the	DT	the	the	the	N	O
occurrence	NN	occurrence	occurrence	occurr	N	O
of	IN	of	of	of	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
,	,	,	,	,	N	O
frequent	JJ	frequent	frequent	frequent	N	O
blood	NN	blood	blood	blood	N	O
cell	NN	cell	cell	cell	N	O
counts	NNS	counts	count	count	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
performed	VBN	performed	performed	perform	N	O
on	IN	on	on	on	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
receiving	VBG	receiving	receiving	receiv	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
.	.	.	.	.	N	O

JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
neutrophil	JJ	neutrophil	neutrophil	neutrophil	N	O
counts	NNS	counts	count	count	N	O
of	IN	of	of	of	N	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
500	CD	500	500	500	N	O
cells	NNS	cells	cell	cell	N	O
mm	JJ	mm	mm	mm	N	O
3	CD	3	3	3	N	O
[	JJ	[	[	[	N	O
see	NN	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Severe	JJ	severe	severe	sever	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
:	:	:	:	:	N	O
Severe	JJ	severe	severe	sever	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	B-Factor
include	VB	include	include	includ	N	O
generalized	JJ	generalized	generalized	gener	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
and	CC	and	and	and	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	B-AdverseReaction
.	.	.	.	.	N	O

Severe	JJ	severe	severe	sever	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
require	VBP	require	require	requir	N	O
immediate	JJ	immediate	immediate	immedi	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
infusion	NN	infusion	infusion	infus	Y	O
and	CC	and	and	and	N	O
administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
should	MD	should	should	should	N	O
receive	VB	receive	receive	receiv	N	O
premedication	NN	premedication	premedication	premed	Y	O
.	.	.	.	.	N	O

JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
who	WP	who	who	who	N	O
have	VBP	have	have	have	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
to	TO	to	to	to	N	O
cabazitaxel	VB	cabazitaxel	cabazitaxel	cabazitaxel	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
formulated	VBN	formulated	formulated	formul	N	O
with	IN	with	with	with	N	O
polysorbate	NN	polysorbate	polysorbate	polysorb	N	O
80	CD	80	80	80	N	O
[	NN	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
Warnings	NNP	warnings	warning	warn	N	O
and	CC	and	and	and	N	O
Precautions	NNP	precautions	precaution	precaut	N	O
(	(	(	(	(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O
\n	CC	\n	\n	\n	N	O
5	CD	5	5	5	N	O
WARNINGS	NNP	warnings	warning	warn	N	O
AND	NNP	and	and	and	N	O
PRECAUTIONS	NNP	precautions	precaution	precaut	N	O

EXCERPT	NN	excerpt	excerpt	excerpt	N	O
:	:	:	:	:	N	O
Bone	NN	bone	bone	bone	N	B-AdverseReaction
marrow	NN	marrow	marrow	marrow	N	I-AdverseReaction
suppression	NN	suppression	suppression	suppress	N	I-AdverseReaction
(	(	(	(	(	N	O
particularly	RB	particularly	particularly	particularli	N	O
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
its	PRP$	its	it	it	N	O
clinical	JJ	clinical	clinical	clinic	N	O
consequences	NNS	consequences	consequence	consequ	N	O
(	(	(	(	(	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
,	,	,	,	,	N	O
neutropenic	JJ	neutropenic	neutropenic	neutropen	N	B-AdverseReaction
infections	NNS	infections	infection	infect	N	I-AdverseReaction
)	)	)	)	)	N	O
:	:	:	:	:	N	O
Monitor	NNP	monitor	monitor	monitor	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
frequently	RB	frequently	frequently	frequent	N	O
to	TO	to	to	to	N	O
determine	VB	determine	determine	determin	N	O
if	IN	if	if	if	N	O
dosage	JJ	dosage	dosage	dosag	N	O
modification	NN	modification	modification	modif	N	O
or	CC	or	or	or	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
G	NNP	g	g	g	N	O
-	:	-	-	-	N	O
CSF	NNP	csf	csf	csf	N	O
is	VBZ	is	is	is	N	O
needed	VBN	needed	needed	need	N	O
.	.	.	.	.	N	O

Primary	JJ	primary	primary	primari	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
with	IN	with	with	with	N	O
G	NNP	g	g	g	N	O
-	:	-	-	-	N	O
CSF	NN	csf	csf	csf	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
risk	NN	risk	risk	risk	N	O
clinical	JJ	clinical	clinical	clinic	N	O
features	NNS	features	feature	featur	N	O
.	.	.	.	.	N	O

Use	NNP	use	use	use	N	O
caution	NN	caution	caution	caution	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hemoglobin	JJ	hemoglobin	hemoglobin	hemoglobin	Y	O
10	CD	10	10	10	N	O
g	NN	g	g	g	N	O
dL	NN	dl	dl	dl	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)(	RB	)(	)(	)(	N	O
4	CD	4	4	4	N	O
)(	JJ	)(	)(	)(	N	O
5.1	CD	5.1	5.1	5.1	N	O
)	)	)	)	)	N	O

Hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
:	:	:	:	:	N	O
Severe	JJ	severe	severe	sever	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Premedicate	NN	premedicate	premedicate	premed	N	O
with	IN	with	with	with	N	O
corticosteroids	NNS	corticosteroids	corticosteroid	corticosteroid	N	O
and	CC	and	and	and	N	O
H2	NNP	h2	h2	h2	N	O
antagonists	NNS	antagonists	antagonist	antagonist	N	O
.	.	.	.	.	N	O

Discontinue	NNP	discontinue	discontinue	discontinu	N	O
infusion	NN	infusion	infusion	infus	Y	O
immediately	RB	immediately	immediately	immedi	N	O
if	IN	if	if	if	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
is	VBZ	is	is	is	N	O
observed	VBN	observed	observed	observ	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
as	IN	as	a	as	N	O
indicated	JJ	indicated	indicated	indic	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)(	RB	)(	)(	)(	N	O
5.2	CD	5.2	5.2	5.2	N	O
)	)	)	)	)	N	O

Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
disorders	NNS	disorders	disorder	disord	N	I-AdverseReaction
:	:	:	:	:	N	O
Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	NN	vomiting	vomiting	vomit	Y	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Mortality	NNP	mortality	mortality	mortal	N	B-AdverseReaction
related	VBD	related	related	relat	N	O
to	TO	to	to	to	N	O
diarrhea	VB	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Rehydrate	NNP	rehydrate	rehydrate	rehydr	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
with	IN	with	with	with	N	O
anti	JJ	anti	anti	anti	N	O
-	:	-	-	-	N	O
emetics	NNS	emetics	emetic	emet	N	O
and	CC	and	and	and	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
diarrheals	NNS	diarrheals	diarrheals	diarrheal	N	O
as	IN	as	a	as	N	O
needed	VBN	needed	needed	need	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
experiencing	VBG	experiencing	experiencing	experienc	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
,	,	,	,	,	N	O
dosage	NN	dosage	dosage	dosag	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
modified	VBN	modified	modified	modifi	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
Deaths	NNS	deaths	death	death	N	B-AdverseReaction
have	VBP	have	have	have	N	O
occurred	VBN	occurred	occurred	occur	N	O
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
,	,	,	,	,	N	O
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
and	CC	and	and	and	N	O
neutropenic	JJ	neutropenic	neutropenic	neutropen	N	B-AdverseReaction
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	I-AdverseReaction
.	.	.	.	.	N	O

Delay	NN	delay	delay	delay	N	O
or	CC	or	or	or	N	O
discontinue	NN	discontinue	discontinue	discontinu	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.3	CD	5.3	5.3	5.3	N	O
)	)	)	)	)	N	O

Renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
cases	NNS	cases	case	case	N	O
with	IN	with	with	with	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
,	,	,	,	,	N	O
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

Identify	NNP	identify	identify	identifi	N	O
cause	NN	cause	cause	caus	N	O
and	CC	and	and	and	N	O
manage	NN	manage	manage	manag	N	O
aggressively	RB	aggressively	aggressively	aggress	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.4	CD	5.4	5.4	5.4	N	O
)	)	)	)	)	N	O

Elderly	JJ	elderly	elderly	elderli	Y	O
patients	NNS	patients	patient	patient	N	O
:	:	:	:	:	N	O
Patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
were	VBD	were	were	were	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
experience	VB	experience	experience	experi	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcomes	NNS	outcomes	outcome	outcom	N	O
not	RB	not	not	not	N	O
related	VBN	related	related	relat	N	O
to	TO	to	to	to	N	O
disease	VB	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
and	CC	and	and	and	N	O
certain	JJ	certain	certain	certain	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
.	.	.	.	.	N	O

Monitor	NNP	monitor	monitor	monitor	N	O
closely	RB	closely	closely	close	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.5	CD	5.5	5.5	5.5	N	O
)(	RB	)(	)(	)(	N	O
6	CD	6	6	6	N	O
)(	JJ	)(	)(	)(	N	O
8.5	CD	8.5	8.5	8.5	N	O
)	)	)	)	)	N	O

Hepatic	JJ	hepatic	hepatic	hepat	N	B-AdverseReaction
impairment	NN	impairment	impairment	impair	N	I-AdverseReaction
:	:	:	:	:	N	O
Reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
dose	NN	dose	dose	dose	N	O
to	TO	to	to	to	N	O
20	CD	20	20	20	N	O
mg	NNS	mg	mg	mg	N	O
m	VBD	m	m	m	N	O
2	CD	2	2	2	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
mild	JJ	mild	mild	mild	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
and	CC	and	and	and	N	O
to	TO	to	to	to	N	O
15	CD	15	15	15	N	O
mg	NNS	mg	mg	mg	N	O
m	VBD	m	m	m	N	O
2	CD	2	2	2	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
moderate	JJ	moderate	moderate	moder	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O

JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

(	(	(	(	(	N	O
5.7	CD	5.7	5.7	5.7	N	O
)(	RB	)(	)(	)(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O

5.1	CD	5.1	5.1	5.1	N	O

Bone	NN	bone	bone	bone	N	O

Marrow	NNP	marrow	marrow	marrow	N	O
Suppression	NN	suppression	suppression	suppress	N	O

Bone	NNP	bone	bone	bone	N	B-AdverseReaction
marrow	NN	marrow	marrow	marrow	N	I-AdverseReaction
suppression	NN	suppression	suppression	suppress	N	I-AdverseReaction
manifested	VBD	manifested	manifested	manifest	N	O
as	IN	as	a	as	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
,	,	,	,	,	N	O
anemia	NN	anemia	anemia	anemia	Y	B-AdverseReaction
,	,	,	,	,	N	O
thrombocytopenia	NN	thrombocytopenia	thrombocytopenia	thrombocytopenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
or	CC	or	or	or	N	O
pancytopenia	NN	pancytopenia	pancytopenia	pancytopenia	Y	B-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Neutropenic	JJ	neutropenic	neutropenic	neutropen	N	B-AdverseReaction
deaths	NNS	deaths	death	death	N	B-AdverseReaction
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	JJ	randomized	randomized	random	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
five	CD	five	five	five	N	O
patients	NNS	patients	patient	patient	N	O
(	(	(	(	(	N	O
1.3%	CD	1.3%	1.3%	1.3%	N	O
)	)	)	)	)	N	O
experienced	VBD	experienced	experienced	experienc	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
infectious	JJ	infectious	infectious	infecti	N	B-AdverseReaction
adverse	JJ	adverse	adverse	advers	N	I-AdverseReaction
events	NNS	events	event	event	N	I-AdverseReaction
(	(	(	(	(	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
or	CC	or	or	or	N	O
septic	JJ	septic	septic	septic	N	B-AdverseReaction
shock	NN	shock	shock	shock	Y	I-AdverseReaction
)	)	)	)	)	N	O
.	.	.	.	.	N	O

All	DT	all	all	all	N	O
had	VBD	had	had	had	N	O
grade	VBN	grade	grade	grade	N	B-Severity
4	CD	4	4	4	N	I-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
one	CD	one	one	one	N	O
had	VBD	had	had	had	N	O
febrile	VBN	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	RB	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
.	.	.	.	.	N	O

One	CD	one	one	one	N	O
additional	JJ	additional	additional	addit	N	O
patient	NN	patient	patient	patient	N	O
's	POS	's	's	's	N	O
death	NN	death	death	death	Y	B-AdverseReaction
was	VBD	was	wa	wa	N	O
attributed	VBN	attributed	attributed	attribut	N	O
to	TO	to	to	to	N	O
neutropenia	VB	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
without	IN	without	without	without	N	B-Negation
a	DT	a	a	a	N	O
documented	JJ	documented	documented	document	N	O
infection	NN	infection	infection	infect	Y	B-AdverseReaction
.	.	.	.	.	N	O

Grade	$	grade	grade	grade	N	B-Severity
3	CD	3	3	3	N	I-Severity
-	:	-	-	-	N	I-Severity
4	CD	4	4	4	N	I-Severity
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
has	VBZ	has	ha	ha	N	O
been	VBN	been	been	been	N	O
observed	VBN	observed	observed	observ	N	O
in	IN	in	in	in	N	O
82%	CD	82%	82%	82%	N	O
of	IN	of	of	of	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	JJ	randomized	randomized	random	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

G	NNP	g	g	g	N	O
-	:	-	-	-	N	O
CSF	NN	csf	csf	csf	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
reduce	VB	reduce	reduce	reduc	N	O
the	DT	the	the	the	N	O
risks	NNS	risks	risk	risk	N	O
of	IN	of	of	of	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	O
complications	NNS	complications	complication	complic	N	O
associated	VBN	associated	associated	associ	N	O
with	IN	with	with	with	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
use	NN	use	use	use	N	O
.	.	.	.	.	N	O

Primary	JJ	primary	primary	primari	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
with	IN	with	with	with	N	O
G	NNP	g	g	g	N	O
-	:	-	-	-	N	O
CSF	NN	csf	csf	csf	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
high	JJ	high	high	high	N	O
-	:	-	-	-	N	O
risk	NN	risk	risk	risk	N	O
clinical	JJ	clinical	clinical	clinic	N	O
features	NNS	features	feature	featur	N	O
(	(	(	(	(	N	O
age	NN	age	age	age	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
,	,	,	,	,	N	O
poor	JJ	poor	poor	poor	N	O
performance	NN	performance	performance	perform	N	O
status	NN	status	status	statu	N	O
,	,	,	,	,	N	O
previous	JJ	previous	previous	previou	N	O
episodes	NNS	episodes	episode	episod	N	O
of	IN	of	of	of	N	O
febrile	JJ	febrile	febrile	febril	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
,	,	,	,	,	N	O
extensive	JJ	extensive	extensive	extens	N	O
prior	JJ	prior	prior	prior	N	O
radiation	NN	radiation	radiation	radiat	N	O
ports	NNS	ports	port	port	N	O
,	,	,	,	,	N	O
poor	JJ	poor	poor	poor	N	O
nutritional	JJ	nutritional	nutritional	nutrit	N	O
status	NN	status	status	statu	N	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
other	JJ	other	other	other	N	O
serious	JJ	serious	serious	seriou	N	O
comorbidities	NNS	comorbidities	comorbidities	comorbid	N	O
)	)	)	)	)	N	O
that	WDT	that	that	that	N	O
predispose	VBP	predispose	predispose	predispos	N	O
them	PRP	them	them	them	N	O
to	TO	to	to	to	N	O
increased	VBN	increased	increased	increas	N	O
complications	NNS	complications	complication	complic	N	O
from	IN	from	from	from	N	O
prolonged	VBN	prolonged	prolonged	prolong	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
.	.	.	.	.	N	O

Therapeutic	JJ	therapeutic	therapeutic	therapeut	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
G	NNP	g	g	g	N	O
-	:	-	-	-	N	O
CSF	NNP	csf	csf	csf	N	O
and	CC	and	and	and	N	O
secondary	JJ	secondary	secondary	secondari	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
considered	VBN	considered	considered	consid	N	O
in	IN	in	in	in	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
considered	VBN	considered	considered	consid	N	O
to	TO	to	to	to	N	O
be	VB	be	be	be	N	O
at	IN	at	at	at	N	O
increased	VBN	increased	increased	increas	N	O
risk	NN	risk	risk	risk	N	O
for	IN	for	for	for	N	O
neutropenia	JJ	neutropenia	neutropenia	neutropenia	Y	O
complications	NNS	complications	complication	complic	N	O
.	.	.	.	.	N	O

Monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
complete	JJ	complete	complete	complet	N	O
blood	NN	blood	blood	blood	N	O
counts	NNS	counts	count	count	N	O
is	VBZ	is	is	is	N	O
essential	JJ	essential	essential	essenti	N	O
on	IN	on	on	on	N	O
a	DT	a	a	a	N	O
weekly	JJ	weekly	weekly	weekli	N	O
basis	NN	basis	basis	basi	N	O
during	IN	during	during	dure	N	O
cycle	NN	cycle	cycle	cycl	N	O
1	CD	1	1	1	N	O
and	CC	and	and	and	N	O
before	IN	before	before	befor	N	O
each	DT	each	each	each	N	O
treatment	NN	treatment	treatment	treatment	N	O
cycle	NN	cycle	cycle	cycl	N	O
thereafter	RB	thereafter	thereafter	thereaft	N	O
so	RB	so	so	so	N	O
that	IN	that	that	that	N	O
the	DT	the	the	the	N	O
dose	NN	dose	dose	dose	N	O
can	MD	can	can	can	N	O
be	VB	be	be	be	N	O
adjusted	VBN	adjusted	adjusted	adjust	N	O
,	,	,	,	,	N	O
if	IN	if	if	if	N	O
needed	VBN	needed	needed	need	N	O
[	NN	[	[	[	N	O
see	NN	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
neutrophils	JJ	neutrophils	neutrophil	neutrophil	Y	O
1	CD	1	1	1	N	O
,	,	,	,	,	N	O
500	CD	500	500	500	N	O
mm	NN	mm	mm	mm	N	O
3	CD	3	3	3	N	O
[	NN	[	[	[	N	O
see	NN	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Caution	NN	caution	caution	caution	N	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
hemoglobin	JJ	hemoglobin	hemoglobin	hemoglobin	Y	O
10	CD	10	10	10	N	O
g	NN	g	g	g	N	O
dl	NN	dl	dl	dl	N	O
.	.	.	.	.	N	O

5.2	CD	5.2	5.2	5.2	N	O
Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	O
Reactions	NNP	reactions	reaction	reaction	N	O

Hypersensitivity	NNP	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
within	IN	within	within	within	N	O
a	DT	a	a	a	N	O
few	JJ	few	few	few	N	O
minutes	NNS	minutes	minute	minut	N	O
following	VBG	following	following	follow	N	O
the	DT	the	the	the	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
of	IN	of	of	of	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
,	,	,	,	,	N	O
thus	RB	thus	thus	thu	N	O
facilities	NNS	facilities	facility	facil	N	O
and	CC	and	and	and	N	O
equipment	NN	equipment	equipment	equip	N	O
for	IN	for	for	for	N	O
the	DT	the	the	the	N	O
treatment	NN	treatment	treatment	treatment	N	O
of	IN	of	of	of	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	O
and	CC	and	and	and	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
available	JJ	available	available	avail	N	O
.	.	.	.	.	N	O

Severe	JJ	severe	severe	sever	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
can	MD	can	can	can	N	B-Factor
occur	VB	occur	occur	occur	N	O
and	CC	and	and	and	N	O
may	MD	may	may	may	N	B-Factor
include	VB	include	include	includ	N	O
generalized	JJ	generalized	generalized	gener	N	B-AdverseReaction
rash	NN	rash	rash	rash	Y	I-AdverseReaction
erythema	NN	erythema	erythema	erythema	Y	B-AdverseReaction
,	,	,	,	,	N	O
hypotension	NN	hypotension	hypotension	hypotens	Y	B-AdverseReaction
and	CC	and	and	and	N	O
bronchospasm	NN	bronchospasm	bronchospasm	bronchospasm	Y	B-AdverseReaction
.	.	.	.	.	N	O

Premedicate	NNP	premedicate	premedicate	premed	N	O
all	DT	all	all	all	N	O
patients	NNS	patients	patient	patient	N	O
prior	RB	prior	prior	prior	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
initiation	NN	initiation	initiation	initi	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
infusion	NN	infusion	infusion	infus	Y	O
of	IN	of	of	of	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.1	CD	2.1	2.1	2.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Observe	NN	observe	observe	observ	N	O
patients	NNS	patients	patient	patient	N	O
closely	RB	closely	closely	close	N	O
for	IN	for	for	for	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
especially	RB	especially	especially	especi	N	O
during	IN	during	during	dure	N	O
the	DT	the	the	the	N	O
first	JJ	first	first	first	N	O
and	CC	and	and	and	N	O
second	JJ	second	second	second	N	O
infusions	NNS	infusions	infusion	infus	N	O
.	.	.	.	.	N	O

Severe	JJ	severe	severe	sever	N	B-Severity
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	B-AdverseReaction
reactions	NNS	reactions	reaction	reaction	N	I-AdverseReaction
require	VBP	require	require	requir	N	O
immediate	JJ	immediate	immediate	immedi	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
infusion	NN	infusion	infusion	infus	Y	O
and	CC	and	and	and	N	O
appropriate	JJ	appropriate	appropriate	appropri	N	O
therapy	NN	therapy	therapy	therapi	N	O
.	.	.	.	.	N	O

JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
severe	JJ	severe	severe	sever	N	O
hypersensitivity	NN	hypersensitivity	hypersensitivity	hypersensit	Y	O
reactions	NNS	reactions	reaction	reaction	N	O
to	TO	to	to	to	N	O
cabazitaxel	VB	cabazitaxel	cabazitaxel	cabazitaxel	N	O
or	CC	or	or	or	N	O
to	TO	to	to	to	N	O
other	JJ	other	other	other	N	O
drugs	NNS	drugs	drug	drug	N	O
formulated	VBN	formulated	formulated	formul	N	O
with	IN	with	with	with	N	O
polysorbate	NN	polysorbate	polysorbate	polysorb	N	O
80	CD	80	80	80	N	O
[	NN	[	[	[	N	O
see	NN	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.3	CD	5.3	5.3	5.3	N	O
Gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
Adverse	NNP	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O

Nausea	NN	nausea	nausea	nausea	Y	B-AdverseReaction
,	,	,	,	,	N	O
vomiting	VBG	vomiting	vomiting	vomit	Y	B-AdverseReaction
and	CC	and	and	and	N	O
severe	JJ	severe	severe	sever	N	B-Severity
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
,	,	,	,	,	N	O
at	IN	at	at	at	N	O
times	NNS	times	time	time	N	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	B-Factor
occur	VB	occur	occur	occur	N	O
.	.	.	.	.	N	O

Death	NNP	death	death	death	Y	B-AdverseReaction
related	VBD	related	related	relat	N	O
to	TO	to	to	to	N	O
diarrhea	VB	diarrhea	diarrhea	diarrhea	Y	B-AdverseReaction
and	CC	and	and	and	N	O
electrolyte	VB	electrolyte	electrolyte	electrolyt	N	B-AdverseReaction
imbalance	NN	imbalance	imbalance	imbal	N	I-AdverseReaction
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	JJ	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
.	.	.	.	.	N	O

Intensive	JJ	intensive	intensive	intens	N	O
measures	NNS	measures	measure	measur	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
required	VBN	required	required	requir	N	O
for	IN	for	for	for	N	O
severe	JJ	severe	severe	sever	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
and	CC	and	and	and	N	O
electrolyte	JJ	electrolyte	electrolyte	electrolyt	N	O
imbalance	NN	imbalance	imbalance	imbal	N	O
.	.	.	.	.	N	O

Antiemetic	JJ	antiemetic	antiemetic	antiemet	N	O
prophylaxis	NN	prophylaxis	prophylaxis	prophylaxi	Y	O
is	VBZ	is	is	is	N	O
recommended	VBN	recommended	recommended	recommend	N	O
.	.	.	.	.	N	O

Treat	NN	treat	treat	treat	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
rehydration	NN	rehydration	rehydration	rehydr	N	O
,	,	,	,	,	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
diarrheal	NN	diarrheal	diarrheal	diarrheal	N	O
or	CC	or	or	or	N	O
anti	VB	anti	anti	anti	N	O
-	:	-	-	-	N	O
emetic	JJ	emetic	emetic	emet	N	O
medications	NNS	medications	medication	medic	N	O
as	IN	as	a	as	N	O
needed	VBN	needed	needed	need	N	O
.	.	.	.	.	N	O

Treatment	JJ	treatment	treatment	treatment	N	O
delay	NN	delay	delay	delay	N	O
or	CC	or	or	or	N	O
dosage	VB	dosage	dosage	dosag	N	O
reduction	NN	reduction	reduction	reduct	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
necessary	JJ	necessary	necessary	necessari	N	O
if	IN	if	if	if	N	O
patients	NNS	patients	patient	patient	N	O
experience	VBP	experience	experience	experi	N	O
Grade	NNP	grade	grade	grade	N	O
3	CD	3	3	3	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.2	CD	2.2	2.2	2.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Gastrointestinal	NNP	gastrointestinal	gastrointestinal	gastrointestin	N	B-AdverseReaction
(	(	(	(	(	N	O
GI	NNP	gi	gi	gi	N	O
)	)	)	)	)	N	O
hemorrhage	NN	hemorrhage	hemorrhage	hemorrhag	Y	I-AdverseReaction
and	CC	and	and	and	N	O
perforation	NN	perforation	perforation	perfor	Y	I-AdverseReaction
,	,	,	,	,	N	O
ileus	NN	ileus	ileus	ileu	Y	B-AdverseReaction
,	,	,	,	,	N	O
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	B-AdverseReaction
,	,	,	,	,	N	O
neutropenic	JJ	neutropenic	neutropenic	neutropen	N	B-AdverseReaction
enterocolitis	NN	enterocolitis	enterocolitis	enterocol	Y	I-AdverseReaction
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
,	,	,	,	,	N	O
have	VBP	have	have	have	N	O
been	VBN	been	been	been	N	O
reported	VBN	reported	reported	report	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.2	CD	6.2	6.2	6.2	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Risk	NN	risk	risk	risk	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
increased	VBN	increased	increased	increas	N	O
with	IN	with	with	with	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	O
,	,	,	,	,	N	O
age	NN	age	age	age	N	O
,	,	,	,	,	N	O
steroid	NN	steroid	steroid	steroid	N	O
use	NN	use	use	use	N	O
,	,	,	,	,	N	O
concomitant	JJ	concomitant	concomitant	concomit	N	O
use	NN	use	use	use	N	O
of	IN	of	of	of	N	O
NSAIDs	NNP	nsaids	nsaid	nsaid	N	O
,	,	,	,	,	N	O
anti	SYM	anti	anti	anti	N	O
-	:	-	-	-	N	O
platelet	NN	platelet	platelet	platelet	N	O
therapy	NN	therapy	therapy	therapi	N	O
or	CC	or	or	or	N	O
anti	VB	anti	anti	anti	N	O
-	:	-	-	-	N	O
coagulants	NNS	coagulants	coagulant	coagul	N	O
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
a	DT	a	a	a	N	O
prior	JJ	prior	prior	prior	N	O
history	NN	history	history	histori	N	O
of	IN	of	of	of	N	O
pelvic	JJ	pelvic	pelvic	pelvic	N	O
radiotherapy	NN	radiotherapy	radiotherapy	radiotherapi	Y	O
,	,	,	,	,	N	O
adhesions	NNS	adhesions	adhesion	adhes	N	O
,	,	,	,	,	N	O
ulceration	NN	ulceration	ulceration	ulcer	N	O
and	CC	and	and	and	N	O
GI	NNP	gi	gi	gi	N	O
bleeding	NN	bleeding	bleeding	bleed	Y	O
.	.	.	.	.	N	O

Abdominal	NNP	abdominal	abdominal	abdomin	N	O
pain	NN	pain	pain	pain	Y	O
and	CC	and	and	and	N	O
tenderness	NN	tenderness	tenderness	tender	Y	O
,	,	,	,	,	N	O
fever	NN	fever	fever	fever	Y	O
,	,	,	,	,	N	O
persistent	JJ	persistent	persistent	persist	N	O
constipation	NN	constipation	constipation	constip	Y	O
,	,	,	,	,	N	O
diarrhea	NN	diarrhea	diarrhea	diarrhea	Y	O
,	,	,	,	,	N	O
with	IN	with	with	with	N	O
or	CC	or	or	or	N	O
without	IN	without	without	without	N	O
neutropenia	NNS	neutropenia	neutropenia	neutropenia	Y	O
,	,	,	,	,	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
early	JJ	early	early	earli	N	O
manifestations	NNS	manifestations	manifestation	manifest	N	O
of	IN	of	of	of	N	O
serious	JJ	serious	serious	seriou	N	O
gastrointestinal	JJ	gastrointestinal	gastrointestinal	gastrointestin	N	O
toxicity	NN	toxicity	toxicity	toxic	N	O
and	CC	and	and	and	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
evaluated	VBN	evaluated	evaluated	evalu	N	O
and	CC	and	and	and	N	O
treated	VBN	treated	treated	treat	N	O
promptly	RB	promptly	promptly	promptli	N	O
.	.	.	.	.	N	O

JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
treatment	NN	treatment	treatment	treatment	N	O
delay	NN	delay	delay	delay	N	O
or	CC	or	or	or	N	O
discontinuation	NN	discontinuation	discontinuation	discontinu	N	O
may	MD	may	may	may	N	O
be	VB	be	be	be	N	O
necessary	JJ	necessary	necessary	necessari	N	O
.	.	.	.	.	N	O

5.4	CD	5.4	5.4	5.4	N	O
Renal	JJ	renal	renal	renal	N	O
Failure	NN	failure	failure	failur	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	JJ	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
of	IN	of	of	of	N	O
any	DT	any	any	ani	N	O
grade	NN	grade	grade	grade	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
4%	CD	4%	4%	4%	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
patients	NNS	patients	patient	patient	N	O
being	VBG	being	being	be	N	O
treated	VBN	treated	treated	treat	N	O
with	IN	with	with	with	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
four	CD	four	four	four	N	O
cases	NNS	cases	case	case	N	O
with	IN	with	with	with	N	O
fatal	JJ	fatal	fatal	fatal	N	B-AdverseReaction
outcome	NN	outcome	outcome	outcom	N	O
.	.	.	.	.	N	O

Most	JJS	most	most	most	N	O
cases	NNS	cases	case	case	N	O
occurred	VBD	occurred	occurred	occur	N	O
in	IN	in	in	in	N	O
association	NN	association	association	associ	N	O
with	IN	with	with	with	N	O
sepsis	NN	sepsis	sepsis	sepsi	Y	B-AdverseReaction
,	,	,	,	,	N	O
dehydration	NN	dehydration	dehydration	dehydr	Y	B-AdverseReaction
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
obstructive	JJ	obstructive	obstructive	obstruct	N	B-AdverseReaction
uropathy	JJ	uropathy	uropathy	uropathi	Y	I-AdverseReaction
[	NN	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6.1	CD	6.1	6.1	6.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Some	DT	some	some	some	N	O
deaths	NNS	deaths	death	death	N	B-AdverseReaction
due	JJ	due	due	due	N	O
to	TO	to	to	to	N	O
renal	JJ	renal	renal	renal	N	B-AdverseReaction
failure	NN	failure	failure	failur	N	I-AdverseReaction
did	VBD	did	did	did	N	O
not	RB	not	not	not	N	O
have	VB	have	have	have	N	O
a	DT	a	a	a	N	O
clear	JJ	clear	clear	clear	N	O
etiology	NN	etiology	etiology	etiolog	N	O
.	.	.	.	.	N	O

Appropriate	JJ	appropriate	appropriate	appropri	N	O
measures	NNS	measures	measure	measur	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
taken	VBN	taken	taken	taken	N	O
to	TO	to	to	to	N	O
identify	VB	identify	identify	identifi	N	O
causes	NNS	causes	cause	caus	N	O
of	IN	of	of	of	N	O
renal	JJ	renal	renal	renal	N	O
failure	NN	failure	failure	failur	N	O
and	CC	and	and	and	N	O
treat	NN	treat	treat	treat	N	O
aggressively	RB	aggressively	aggressively	aggress	N	O
.	.	.	.	.	N	O

5.5	CD	5.5	5.5	5.5	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Elderly	NNP	elderly	elderly	elderli	Y	O
Patients	NNS	patients	patient	patient	N	O

In	IN	in	in	in	N	O
the	DT	the	the	the	N	O
randomized	JJ	randomized	randomized	random	N	O
clinical	JJ	clinical	clinical	clinic	N	O
trial	NN	trial	trial	trial	N	O
,	,	,	,	,	N	O
3	CD	3	3	3	N	O
of	IN	of	of	of	N	O
131	CD	131	131	131	N	O
(	(	(	(	(	N	O
2%	CD	2%	2%	2%	N	O
)	)	)	)	)	N	O
patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
and	CC	and	and	and	N	O
15	CD	15	15	15	N	O
of	IN	of	of	of	N	O
240	CD	240	240	240	N	O
(	(	(	(	(	N	O
6%	CD	6%	6%	6%	N	O
)	)	)	)	)	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
died	VBN	died	died	die	N	B-AdverseReaction
of	IN	of	of	of	N	O
causes	NNS	causes	cause	caus	N	O
other	JJ	other	other	other	N	O
than	IN	than	than	than	N	O
disease	JJ	disease	disease	diseas	N	O
progression	NN	progression	progression	progress	N	O
within	IN	within	within	within	N	O
30	CD	30	30	30	N	O
days	NNS	days	day	day	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
last	JJ	last	last	last	N	O
cabazitaxel	NN	cabazitaxel	cabazitaxel	cabazitaxel	N	O
dose	NN	dose	dose	dose	N	O
.	.	.	.	.	N	O

Patients	NNS	patients	patient	patient	N	O
65	CD	65	65	65	N	O
years	NNS	years	year	year	N	O
of	IN	of	of	of	N	O
age	NN	age	age	age	N	O
are	VBP	are	are	are	N	O
more	RBR	more	more	more	N	O
likely	JJ	likely	likely	like	N	O
to	TO	to	to	to	N	O
experience	VB	experience	experience	experi	N	O
certain	JJ	certain	certain	certain	N	O
adverse	JJ	adverse	adverse	advers	N	O
reactions	NNS	reactions	reaction	reaction	N	O
,	,	,	,	,	N	O
including	VBG	including	including	includ	N	O
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	B-AdverseReaction
and	CC	and	and	and	N	O
febrile	JJ	febrile	febrile	febril	N	B-AdverseReaction
neutropenia	NN	neutropenia	neutropenia	neutropenia	Y	I-AdverseReaction
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Adverse	JJ	adverse	adverse	advers	N	O
Reactions	NNP	reactions	reaction	reaction	N	O
(	(	(	(	(	N	O
6	CD	6	6	6	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.5	CD	8.5	8.5	8.5	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

5.6	CD	5.6	5.6	5.6	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
Hepatic	NNP	hepatic	hepatic	hepat	N	O
Impairment	NNP	impairment	impairment	impair	N	O

Cabazitaxel	NNP	cabazitaxel	cabazitaxel	cabazitaxel	N	O
is	VBZ	is	is	is	N	O
extensively	RB	extensively	extensively	extens	N	O
metabolized	VBN	metabolized	metabolized	metabol	N	O
in	IN	in	in	in	N	O
the	DT	the	the	the	N	O
liver	NN	liver	liver	liver	N	O
.	.	.	.	.	N	O

JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
is	VBZ	is	is	is	N	O
contraindicated	VBN	contraindicated	contraindicated	contraind	N	O
in	IN	in	in	in	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
severe	JJ	severe	severe	sever	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
(	(	(	(	(	N	O
total	JJ	total	total	total	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
3	CD	3	3	3	N	O
ULN	NNP	uln	uln	uln	N	O
)	)	)	)	)	N	O
[	VBD	[	[	[	N	O
see	JJ	see	see	see	N	O
Contraindications	NNP	contraindications	contraindication	contraind	N	O
(	(	(	(	(	N	O
4	CD	4	4	4	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Dose	NNP	dose	dose	dose	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
reduced	VBN	reduced	reduced	reduc	N	O
for	IN	for	for	for	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
mild	NN	mild	mild	mild	N	O
(	(	(	(	(	N	O
total	JJ	total	total	total	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
1	CD	1	1	1	N	O
to	TO	to	to	to	N	O
1.5	CD	1.5	1.5	1.5	N	O
ULN	NNP	uln	uln	uln	N	O
or	CC	or	or	or	N	O
AST	NNP	ast	ast	ast	N	O
1.5	CD	1.5	1.5	1.5	N	O
ULN	NNP	uln	uln	uln	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
moderate	JJ	moderate	moderate	moder	N	O
(	(	(	(	(	N	O
total	JJ	total	total	total	N	O
bilirubin	NN	bilirubin	bilirubin	bilirubin	Y	O
1.5	CD	1.5	1.5	1.5	N	O
to	TO	to	to	to	N	O
3.0	CD	3.0	3.0	3.0	N	O
ULN	NNP	uln	uln	uln	N	O
and	CC	and	and	and	N	O
any	DT	any	any	ani	N	O
AST	NNP	ast	ast	ast	N	O
)	)	)	)	)	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
,	,	,	,	,	N	O
based	VBN	based	based	base	N	O
on	IN	on	on	on	N	O
tolerability	NN	tolerability	tolerability	toler	N	O
data	NNS	data	data	data	N	O
in	IN	in	in	in	N	O
these	DT	these	these	these	N	O
patients	NNS	patients	patient	patient	N	O
[	VBP	[	[	[	N	O
see	JJ	see	see	see	N	O
Dosage	NNP	dosage	dosage	dosag	N	O
and	CC	and	and	and	N	O
Administration	NNP	administration	administration	administr	N	O
(	(	(	(	(	N	O
2.3	CD	2.3	2.3	2.3	N	O
)	)	)	)	)	N	O
and	CC	and	and	and	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.7	CD	8.7	8.7	8.7	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

Administration	NN	administration	administration	administr	N	O
of	IN	of	of	of	N	O
cabazitaxel	NNS	cabazitaxel	cabazitaxel	cabazitaxel	N	O
to	TO	to	to	to	N	O
patients	NNS	patients	patient	patient	N	O
with	IN	with	with	with	N	O
mild	JJ	mild	mild	mild	N	O
and	CC	and	and	and	N	O
moderate	JJ	moderate	moderate	moder	N	O
hepatic	JJ	hepatic	hepatic	hepat	N	O
impairment	NN	impairment	impairment	impair	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
undertaken	VBN	undertaken	undertaken	undertaken	N	O
with	IN	with	with	with	N	O
caution	NN	caution	caution	caution	N	O
and	CC	and	and	and	N	O
close	JJ	close	close	close	N	O
monitoring	NN	monitoring	monitoring	monitor	N	O
of	IN	of	of	of	N	O
safety	NN	safety	safety	safeti	N	O
.	.	.	.	.	N	O

5.7	CD	5.7	5.7	5.7	N	O
Embryo	NNP	embryo	embryo	embryo	N	O
-	:	-	-	-	N	O
Fetal	JJ	fetal	fetal	fetal	N	O
Toxicity	NN	toxicity	toxicity	toxic	N	O

JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
is	VBZ	is	is	is	N	O
not	RB	not	not	not	N	O
indicated	VBN	indicated	indicated	indic	N	O
for	IN	for	for	for	N	O
use	NN	use	use	use	N	O
in	IN	in	in	in	N	O
female	JJ	female	female	femal	N	O
patients	NNS	patients	patient	patient	N	O
.	.	.	.	.	N	O

JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
can	MD	can	can	can	N	B-Factor
cause	VB	cause	cause	caus	N	O
fetal	JJ	fetal	fetal	fetal	N	B-AdverseReaction
harm	NN	harm	harm	harm	N	I-AdverseReaction
when	WRB	when	when	when	N	O
administered	VBN	administered	administered	administ	N	O
to	TO	to	to	to	N	O
a	DT	a	a	a	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
woman	NN	woman	woman	woman	N	O
.	.	.	.	.	N	O

In	IN	in	in	in	N	O
non	JJ	non	non	non	N	O
-	:	-	-	-	N	O
clinical	JJ	clinical	clinical	clinic	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
rats	NNS	rats	rat	rat	N	B-Animal
and	CC	and	and	and	N	O
rabbits	NNS	rabbits	rabbit	rabbit	N	B-Animal
,	,	,	,	,	N	O
cabazitaxel	NN	cabazitaxel	cabazitaxel	cabazitaxel	N	O
was	VBD	was	wa	wa	N	O
embryotoxic	JJ	embryotoxic	embryotoxic	embryotox	N	B-AdverseReaction
,	,	,	,	,	N	O
fetotoxic	JJ	fetotoxic	fetotoxic	fetotox	N	B-AdverseReaction
,	,	,	,	,	N	O
and	CC	and	and	and	N	O
abortifacient	NN	abortifacient	abortifacient	abortifaci	N	B-AdverseReaction
at	IN	at	at	at	N	O
exposures	NNS	exposures	exposure	exposur	N	O
significantly	RB	significantly	significantly	significantli	N	O
lower	JJR	lower	lower	lower	N	O
than	IN	than	than	than	N	O
those	DT	those	those	those	N	O
expected	VBN	expected	expected	expect	N	O
at	IN	at	at	at	N	O
the	DT	the	the	the	N	O
recommended	JJ	recommended	recommended	recommend	N	O
human	NN	human	human	human	N	O
dose	VBD	dose	dose	dose	N	O
level	NN	level	level	level	N	O
.	.	.	.	.	N	O

There	EX	there	there	there	N	O
are	VBP	are	are	are	N	O
no	DT	no	no	no	N	O
adequate	JJ	adequate	adequate	adequ	N	O
and	CC	and	and	and	N	O
well	RB	well	well	well	N	O
-	:	-	-	-	N	O
controlled	VBN	controlled	controlled	control	N	O
studies	NNS	studies	study	studi	N	O
in	IN	in	in	in	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
women	NNS	women	woman	women	N	O
using	VBG	using	using	use	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
.	.	.	.	.	N	O

If	IN	if	if	if	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
is	VBZ	is	is	is	N	O
used	VBN	used	used	use	N	O
during	IN	during	during	dure	N	O
pregnancy	NN	pregnancy	pregnancy	pregnanc	Y	O
,	,	,	,	,	N	O
or	CC	or	or	or	N	O
if	IN	if	if	if	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
becomes	VBZ	becomes	becomes	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
while	IN	while	while	while	N	O
taking	VBG	taking	taking	take	N	O
this	DT	this	this	thi	N	O
drug	NN	drug	drug	drug	N	O
,	,	,	,	,	N	O
the	DT	the	the	the	N	O
patient	NN	patient	patient	patient	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
apprised	VBN	apprised	apprised	appris	N	O
of	IN	of	of	of	N	O
the	DT	the	the	the	N	O
potential	JJ	potential	potential	potenti	N	O
hazard	NN	hazard	hazard	hazard	N	O
to	TO	to	to	to	N	O
the	DT	the	the	the	N	O
fetus	NN	fetus	fetus	fetu	N	O
.	.	.	.	.	N	O

Females	NNS	females	female	femal	N	O
of	IN	of	of	of	N	O
childbearing	VBG	childbearing	childbearing	childbear	N	O
potential	JJ	potential	potential	potenti	N	O
should	MD	should	should	should	N	O
be	VB	be	be	be	N	O
advised	VBN	advised	advised	advis	N	O
to	TO	to	to	to	N	O
avoid	VB	avoid	avoid	avoid	N	O
becoming	VBG	becoming	becoming	becom	N	O
pregnant	JJ	pregnant	pregnant	pregnant	Y	O
during	IN	during	during	dure	N	O
treatment	NN	treatment	treatment	treatment	N	O
with	IN	with	with	with	N	O
JEVTANA	NNP	jevtana	jevtana	jevtana	N	O
[	NNP	[	[	[	N	O
see	VBP	see	see	see	N	O
Use	NNP	use	use	use	N	O
in	IN	in	in	in	N	O
Specific	NNP	specific	specific	specif	N	O
Populations	NNP	populations	population	popul	N	O
(	(	(	(	(	N	O
8.1	CD	8.1	8.1	8.1	N	O
)	)	)	)	)	N	O
]	NN	]	]	]	N	O
.	.	.	.	.	N	O

